Sensei Biotherapeutics (SNSE) News Today → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free SNSE Stock Alerts $0.83 +0.04 (+5.06%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 6:51 PM | seekingalpha.comSNSE Sensei Biotherapeutics, Inc.May 26 at 3:52 AM | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Given Overweight Rating at StephensMay 26 at 3:20 AM | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Given "Buy" Rating at HC WainwrightMay 25, 2024 | markets.businessinsider.comBuy Rating on Sensei Biotherapeutics: Innovations and Promising Clinical DevelopmentsMay 24, 2024 | msn.comSensei stock plunges 46% in wake of Phase 1 dataMay 24, 2024 | investorplace.comWhy Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?May 23, 2024 | globenewswire.comSensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101May 14, 2024 | msn.comStephens & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Overweight RecommendationMay 13, 2024 | markets.businessinsider.comBuy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial StabilityMay 9, 2024 | investorplace.comSNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024May 9, 2024 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 24, 2024 | globenewswire.comSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingApril 9, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceApril 4, 2024 | uk.investing.comSensei Biotherapeutics CFO Erin Colgan to resignApril 4, 2024 | globenewswire.comSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentMarch 22, 2024 | globenewswire.comSensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumMarch 6, 2024 | globenewswire.comSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific ConferencesFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical TrialsFebruary 28, 2024 | globenewswire.comSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsFebruary 9, 2024 | msn.comSensei Biotherapeutics Announces Board Member Resignation and Consultant RoleFebruary 9, 2024 | msn.comSensei Biotherapeutics Streamlines Board, Appoints Interim ChairFebruary 7, 2024 | finance.yahoo.comSensei Biotherapeutics to Present at Upcoming ConferencesJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety DataJanuary 4, 2024 | finance.yahoo.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesDecember 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)December 4, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy RecommendationNovember 7, 2023 | msn.comSensei Biotherapeutics GAAP EPS of -$0.28 in-lineNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingOctober 25, 2023 | finance.yahoo.comSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingOctober 24, 2023 | bizjournals.comRockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from NasdaqOctober 23, 2023 | finance.yahoo.comSensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023September 27, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®September 21, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceSeptember 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceAugust 30, 2023 | uk.finance.yahoo.comSNSE - Sensei Biotherapeutics, Inc.August 3, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 2, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth ConferenceJune 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”June 1, 2023 | finance.yahoo.comSensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid TumorsMay 31, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceMay 10, 2023 | markets.businessinsider.comCitigroup Remains a Buy on Sensei Biotherapeutics (SNSE)May 9, 2023 | finance.yahoo.comSensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsApril 20, 2023 | finance.yahoo.comSensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking AntibodyApril 18, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023April 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual ConferenceMarch 30, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual SymposiumMarch 28, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business HighlightsMarch 21, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here SNSE Media Mentions By Week SNSE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNSE News Sentiment▼0.120.79▲Average Medical News Sentiment SNSE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNSE Articles This Week▼120▲SNSE Articles Average Week Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRKR News RVPH News PMN News XGN News RNXT News LEXX News SPRB News UNCY News VYNE News JAGX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNSE) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeHe Is Giving Away BitcoinCrypto Swap ProfitsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
